Hostname: page-component-7b7567c8c-kwt9d Total loading time: 0 Render date: 2026-11-14T08:41:55.792Z Has data issue: false hasContentIssue false
  • English
  • Français

New Single-Isomer Compounds on the Horizon

Published online by Cambridge University Press:  07 November 2014

Joseph Gal
Get accessRights & Permissions [Opens in a new window]

Abstract

In 1992, the Food and Drug Administration (FDA) issued new guidelines governing stereoisomerism in new-drug development. The guidelines strongly encourage the development of single isomers and discourage stereoisomeric (eg, racemic) mixtures. As a result, most new chiral drugs are being developed as single enantiomers (ie, single isomers). There are three mechanisms for the identification and development of new single-isomer drugs: chiral switches (CS), chiral metashifts (CM), and new single-isomer chemical entities (NSICEs). In a CS, one of the two enantiomers of an established racemate is developed as a new drug, with the expectation that the single-isomer form has advantages over the racemic parent in terms of efficacy and/or adverse effects. Many new CS drugs are in development, eg, (S)-oxybutynin for urinary incontinence and escitalopram for depression. In a CM, a chiral metabolite of a drug is developed, in single-isomer form, as an agent with advantages over the parent. Among the current CM drugs in development are (+)-norcisapride (safer GI prokinetic agent than the racemic parent cisapride) and (S)-desmethylzopiclone (antianxiety agent, metabolite of the sedative-hypnotic zopi-clone). Many NSICEs are in development, eg, rosuvastatin as an antihypercholesterolemic, posaconazole as an antifungal, sitafloxacin as a fluoroquinolone antibacterial, pregabalin as an anticonvulsant, abarelix as an antineoplastic, etc. As in the development of any new drug, not every single-isomer candidate will reach the clinic, but there is no doubt that the move to single-isomer agents is an important step forward in the search for better and safer drugs.

Information

Type
Research Article
Information
CNS Spectrums , Volume 7 , Issue S1: The Biological and Clinical Significance of Single Isomers , April 2002, pp. 45 - 54
Copyright
Copyright © Cambridge University Press 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1.Foye, WO. Medicinals of plant origin: historical aspects. In: Foye, WO, Lemke, TL, Williams, DA, eds. Principles of Medicinal Chemistry, 4th ed. Media, Pa: Lippincott Williams & Wilkins; 1995:7–11.Google Scholar
2.Reisine, T, Pasternak, G. Opioid analgesics and antagonists. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw Hill; 1996:521.Google Scholar
3.Nunn, JF. Ancient Egyptian Medicine. Norman, Okla: University of Oklahoma Press; 1996:153–156.Google ScholarPubMed
4.Ariens, EJ, Wuis, EW. Bias in pharmacokinetics and clinical pharmacology. Clin Pharmacol Ther. 1987;42:361–363.CrossRefGoogle ScholarPubMed
5.Eiehelbaum, M, Gross, AS. Stereochemical aspects of drug action and disposition. Adv Drug Res. 1996;28:1–64.CrossRefGoogle Scholar
6.FDA's policy for the development of new stereoisomeric drugs. Federal Register. 1992;57:222149Google Scholar
7.Stinson, SC. Chiral drugs. Chem Engin News. 2000;78:55–78.CrossRefGoogle Scholar
8.Rapaka, RS, Hawks, RL. Medications Development: Drug Discovery, Databases, and Computer-Aided Drug Design. NIDA Research Monograph 134. Rockville, Md: National Institute on Drug Abuse; 1996.Google Scholar
9.Tucker, GT. Chiral switches. Lancet. 2000;355:1085–1087.CrossRefGoogle ScholarPubMed
10.Stinson, SC. Sepracor: skating on thin ‘ice.’ Chem Engin News. 1998;76:11–13.CrossRefGoogle Scholar
11.Stinson, SC. Counting on chiral drugs. Chem Engin News. 1998;76:83–104.CrossRefGoogle Scholar
12.Maria, VAJ, Victorino, RMM. Hypersensitivity immune-reaction as a mechanism for dilevalol-associated hepatitis. Ann Pharmacother. 1992;26:924–926.CrossRefGoogle ScholarPubMed
13.Doggrell, SA, Brown, L. D-Sotalol: death by the SWORD or deserving further consideration for clinical use? Exp Opin Investig Drugs. 2000;9:1625–1634.CrossRefGoogle ScholarPubMed
14.Thayer, A. Eli Lilly pulls the plug on Prozac isomer drug. Chem Engin News. 2000;78:8.CrossRefGoogle Scholar
15.Mareev, VY. Congestive heart failure and ventricular arrhythmias. Problems of treatment. Kardiologiya. 1996;36:4–12.Google Scholar
16.Jones, SE, Shuba, LM, Zhabyeyev, P, McCullough, JR, McDonald, TF. Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K+ currents and action potentials. Br J Pharmacol. 2000;131:245–254.CrossRefGoogle ScholarPubMed
17.Smith, ER, Wright, SE, Aberg, G, Fang, Y, McCullough, JR. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethy-loxybutynin and their enantiomers with those of racemic terodiline. Arzneimittelforschung. 1998;48:1012–1018.Google ScholarPubMed
18.Hyttel, J, Bogeso, KP, Perregaard, J, Sanchez, C. The pharmacological effect of Citalopram resides in the (S)-(+)-enantiomer. J Neural Transm. 1992;88:157–160.CrossRefGoogle ScholarPubMed
19.Greenblatt, DJ, von Moltke, LL, Giancarlo, GM, et al.Escitalopram metabolism in vitro. Clin Pharmacol Ther. 2001;69(suppl S):49.Google Scholar
20.Hatsukami, D, Lexau, B, Nelson, D, Pentel, PR, Sofuoglu, M, Goldman, A. Effects of cotinine on cigarette self-administration. Psychopharmacology. 1998;138:184–189.CrossRefGoogle ScholarPubMed
21.Green, TA, Phillips, SB, Crooks, PA, Dwoskin, LP, Bardo, MT. Nornicotine pretreatment decreases intravenous nicotine self-administration in rats. Psychopharmacology. 2000;152:289–294.CrossRefGoogle ScholarPubMed
22.Smalley, W, Shatin, D, Wysowski, DK, et al.Contraindicated use of cisapride-impact of food and drug-administration regulatory action. JAMA. 2000;294:3036–3039.CrossRefGoogle Scholar
23.Click, SD, Haskey, RE, Maisonneuve, IM, et al.Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol. 2000;397:93–102.Google Scholar
24.Stein, EA, Lamkin, G, Laskarzewski, PM, et al.ZD4522 (rosuvastatin) compared with diet and maximal lipid therapy in patients with heterozygous familial hypercholesterolemia. J Amer Coll Cardiol. 2001;37(suppl A):abstract 1261-173, 291A.Google Scholar
25.Paeletti, R, Fahmy, M, Mahla, G, et al.ZD4522 is superior to pravastatin and simvastatin in reducing low density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low density lipoprotein cholesterol guidelines. J Amer Coll Cardiol. 2001;37(suppl A):abstract 1261-174, 291A.Google Scholar
26.Davidson, MH, Ma, PTS, Stein, E, et al.ZD4522 is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia. [abstract] J Amer Coll Cardiol. 2001;37(suppl A):abstract 1261-175, 292A.Google Scholar
27.Stein, E, Strutt, KL, Miller, E, et al.ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia, [abstract] J Amer Coll Cardiol. 2001;37(suppl A):abstract 1261-176, 292A.Google Scholar
28.Lipka, LJ, LeBeaut, AP, Veltri, EP, et al.Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by SCH58235: Pooled analysis of the two phase II studies, [abstract] J Amer Coll Cardiol. 2000;35(suppl A):abstract, 257A.Google Scholar
29.VanHeek, M, France, CF, Compton, DS, et al.In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther. 1997;283:157–163.Google Scholar
30.Galgiani, JN, Lewis, ML. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother. 1997;41:180–183.CrossRefGoogle ScholarPubMed
31.Barchiesi, F, Schimizzi, AM, Najvar, LK, et al.Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob Agents Chemother. 2001;45:1355–1359.CrossRefGoogle ScholarPubMed
32.Lomaestro, BM, Piatek, MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother. 1998;32:915–928.CrossRefGoogle ScholarPubMed
33.Giamarellou-Bourboulis, EJ, Sambatakou, H, Grecka, P, Chryssouli, Z, Giamarellou, H. Sitafloxacin (DU-6859a) and trovafloxacin: postantibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 1999;34:301–307.CrossRefGoogle ScholarPubMed
34.Furman, PA, Jeffrey, J, Keifer, LL, et al.Mechanism of action of 1-(-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-(-D-dioxolane guanosine. Antimicrob Agents Chemother. 2001;45:158–165.CrossRefGoogle Scholar
35.Chen, HC, Schinazi, RF, Rajagopalan, P, et al.Pharmacokinetics of (-)-(-D-dioxolane guanine and prodrug (-)-(-D-2,6-diaminopurine dioxolane in rats and monkeys. AIDS Res Human Retrov. 1999;15:1625–1630.CrossRefGoogle ScholarPubMed
36.Wang, LH, Bigley, JW, Brosnan-Cook, M, et al, DAPD-101 Clinical Trial Group. Poster presented at 8th Conference on Retroviruses and Opportunistic Infections. 02 4-8, 2001; Chicago, Ill.Google Scholar
37.Tattersall, FD, Rycroft, W, Cumberbatch, M, et al.The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water-soluble phosphoryl prodrug, L759,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology. 2000;39:652–663.CrossRefGoogle Scholar
38.Rupniak, NMJ, Kramer, MS. Discovery of the anti-depressant and anti-emetic efficay of substance P receptor (NK1) antagonists. Trends Pharmacol Sci. 1999;20:485–490.CrossRefGoogle Scholar
39.Maubach, KA, Rupniak, NMJ, Kramer, MS, Hill, RG. Novel strategies for pharmacotherapy of depression. Curr Opinion Chem Biol. 1999;3:481–488.CrossRefGoogle ScholarPubMed
40.Block, GA, Rue, D, Panebianco, D, et al.The substance P antagonist L-754,030 (MK-0869) is ineffective in the treatment of postherpetic neuralgia. Neurology. 1998;50(suppl 4):P04084.Google Scholar
41.Huskey, SE, Luffer-Atlas, D, Dean, BJ, McGowan, EM, Feeney, WP, Chiu, SH. Substance P receptor antagonist I: Conversion of phosphoramidate prodrug after i.v. administration to rats and dogs. Drug Metab Disp. 1999;27:1367–1373.Google ScholarPubMed
42.Bryans, JS, Wustrow, DJ. 3-Substituted GABA analogs with central nervous system activity: A review. Med Res Rev. 1999;19:149–177.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
43.Bialer, M, Johannessen, SI, Kupferberg, HJ, Levy, Rh, Loiseau, P, Perucca, E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Research. 1999;34:1–41.CrossRefGoogle ScholarPubMed
44.Jefferson, JW. Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). J Clin Psych. 2001;62:50–56.Google ScholarPubMed
45.Watkins, KJ. Peptides: A boom in the making. Chem Engin News. 2001;79(2):11–15.CrossRefGoogle Scholar
46.Doehn, C, Jocham, D. Technology evaluation: Abarelix, Praecis pharmaceuticals. Curr Opin Mol Ther. 2000;2:579–585.Google ScholarPubMed